检索结果 - Andrew Kean Seng Lim
- Showing 1 - 2 results of 2
-
1
-
2
Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer 由 R. Charles Coombes, P. D. Badman, Jingky Lozano-Kühne, X. Liu, Iain R. Macpherson, Ishtiaq Husain Zubairi, Richard D. Baird, Nitzan Rosenfeld, Javier Garciá Corbacho, Nicola Cresti, Ruth Plummer, Andrew J. Armstrong, R. Allerton, Dónal Landers, H. Nicholas, L. McLellan, Andrew Kean Seng Lim, Florent Moulière, Olivier E. Pardo, Veronica Ferguson, Michael J. Seckl
出版 2022Artigo
相关主题
Cancer
Internal medicine
Medicine
Adverse effect
Anastrozole
Aromatase
Aromatase inhibitor
Breast cancer
Clinical endpoint
Clinical trial
Complication
Disease
Estrogen receptor
Fulvestrant
Hip dysplasia
Letrozole
Meta-analysis
Metastatic breast cancer
Multivariate analysis
Oncology
Osteotomy
Phases of clinical research
Progressive disease
Radiography
Response Evaluation Criteria in Solid Tumors
Surgery
Survivorship curve
Tolerability
Total hip arthroplasty
Univariate analysis